Abstract
The aim of this paper is to study possible synergic effects between crystallization-inhibitor molecules of low molecular weight on the hydroxyapatite and brushite crystal nucleation. Kinetic-turbidimetric measurements were performed to follow the nucleation process in synthetic urine at 37 °C. Only pyrophosphate + phytate mixture manifested synergic effects on the brushite nucleation, whereas the mixture pyrophosphate +citrate exhibited synergic effects only on the hydroxyapatite nucleation. It seems clear that synergic effects between the crystallization inhibitory capacity of some substances in urine can take place and as a consequence, the high crystallization inhibitory capacity of healthy urine could be assigned not only to the individualinhibitory capacity of each product but also to the synergic effects between different products.
Similar content being viewed by others
References
Fleisch H, Bisaz S. Isolation from urine of pyrophosphate, a calcification inhibitor. Am J Physiol 1962; 203: 671.
Grases F, Masárová L, Söhnel O, Costa-Bauzá A. Agglomeration of calcium oxalate monohydrate in synthetic urine. Brit J Urol 1992; 70: 240.
Grases F, García-Ferragut L, Costa-Bauzá A. Study of the early stages of renal stone formation: experimental model using urothelium of pig urinary bladder. Urol Res 1996; 24: 305.
Grases F, García-Ferragut L, Costa-Bauzá A, March JG. Study of the effects of different substances on the early stages of papillary stone formation. Nephron 1996; 73: 561.
Grases F, Söhnel O, Villacampa AI, March JG. Phosphates precipitating from artificial urine and fine structure of phos-phate renal calculi. Clin Chim Acta 1996; 244: 45.
Grases F, Costa-Bauzá A, Königsberger E, Königsberger L-C. Kinetic versus thermodynamic factors in calcium renal lithiasis. Int Urol Nephrol 2000; 32: 19.
Hess B. The role of Tamm-Horsfall glycoprotein and nephrocalcin in calcium oxalate monohydrate crystallization processes. Scanning Microsc 1991; 5: 689.
Hess B. Tamm-Horsfall glycoprotein-inhibitor or promoter of calcium oxalate monohydrate crystallization processes? Urol Res 1992; 20: 83.
Hoyer JR. Uropontin in urinary calcium stone formation. Miner Electrolyte Metab 1995; 20: 385.
Meyer JL, Smith LH. Growth of calcium oxalate crystals. II. Inhibition by natural crystal growth inhibitors. Invest Urol 1975; 13: 36.
Nakagawa Y, Abram V, Coe FL. Isolation of calcium oxalate crystal growth inhibitor from rat kidney and urine. Am J Physiol 1984; 247: F765.
Pak CYC. Citrate and renal calculi. Miner Electrolyte Metab 1987; 13: 257.
Ryall RL, Harnett RM, Marshal VR. The effect of urine, pyro-phosphate, citrate, magnesium and glycosaminoglycans on the growth and aggregation of calcium oxalate crystals in vitro. Clin Chim Acta 1981; 112: 349.
Scurr DS, Robertson WG. Modifiers of calcium oxalate crystallization found in urine III. Studies on the role of Tamm Horsfall mucoprotein and of ionic stregth. J Urol 1986; 136: 505.
See WA, Williams RD. Urothlial injury and clotting cascade activation: common denominators in particulate adherence to urothelial surfaces. J Urol 1992; 147: 541.
Shum DK, Gohel MD. Separate effects of urinary chondroitin sulphate and heparan sulphate upon the crystallization of urinary calcium oxalate: differences between stone formers and normal controls. Clin Sci 1993; 85: 33.
Worcester EM, Nakagawa Y, Coe FL. Glycoprotein calcium oxalate crystal growth inhibitor in urine. Miner Electrolyte Metab 1987; 13: 267.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Costa-Bauzá, A., Barceló, C., Perelló, J. et al. Synergism between the brushite and hydroxyapatite urinary crystallization inhibitors. Int Urol Nephrol 34, 447–451 (2002). https://doi.org/10.1023/A:1025671019653
Issue Date:
DOI: https://doi.org/10.1023/A:1025671019653